Multiparametric MRI is the benchmark in prostate cancer imaging. It has revolutionized detection and diagnosis. It enables qualified patients to have a tailored focal therapy as an alternative to whole-gland treatments. Now, however, there’s a movement to expand use of a shortcut called biparametric MRI.

What’s the difference between multiparametric MRI and biparametric MRI?

There is a qualitative difference between multiparametric MRI and biparametric MRI.

Multiparametric MRI (mpMRI) utilizes three parameters, or imaging sequences, to produce a 3-dimensional portrait of the prostate. When all three combine, they define specific characteristics that distinguish significant prostate cancer (PCa) from healthy tissue.

The first two sequences together are the “workhorse” of prostate imaging. As I have previously written,

1. T2-weighted imaging reveals the different zones and capsule anatomy of the prostate. By itself, it may detect PCa in the peripheral zone, but in many cases, especially in the transitional zone, the results may be ambiguous.
2. Diffusion weighted imaging (DWI) distinguishes PCa from healthy cells based on the natural movement (diffusion) of water molecules within tissues. Because the density of tumor cells restricts water motion, a calculation of the apparent diffusion coefficient, or ADC, can be made. The lower the ADC value, the greater the restriction and therefore likelihood of cancer. DWI sequences can be varied according to the “b value” (strength of the magnetic field) so that at higher b values the sensitivity to water diffusion is increased while anatomic detail is filtered out. While suspicious areas show up as dark regions on an ADC map, images with the highest b values show the same regions as bright spots. Therefore, it’s worth the scanning time to run ADC and high b value DWI sequences.

The third sequence adds a key detail, revealing a cancer feature not picked up by the other two:

3. Dynamic contrast enhanced (DCE) MRI relies on the intravenous injection of a contrast agent that can reveal the abnormal blood flow associated with cancerous tumors. According to [one] article, “It has been shown to be able to detect significant disease in up to 93% of cases.”^[i]

Using all three parameters during a scan is called multiparametric MRI (multi means more than two, as in multiplex cinema). The imaging information is complete, but it is not a diagnosis. However, mpMRI findings determine if a diagnostic biopsy is needed. Thanks to clear visual definition, mpMRI can also be used in real time to guide biopsy needles into the suspicious area. This is called an in-bore MRI-guided targeted biopsy, the most accurate method for PCa diagnosis using the fewest needles.

Biparametric MRI (bpMRI) uses just the first two (“workhorse”) sequences without DCE. Bi means two, as in bifocal glasses. Like mpMRI, bpMRI gives important information. What’s missing, though, is confirming a cancerous tumor based on evidence of abnormal blood flow—picked up only by DCE.

Is there an advantage of bpMRI over mpMRI?

Many experts are urging more use of bpMRI because it has efficiency and economic advantages. As stated in a December, 2025 paper published in JAMA (Journal of the American Medical Association), “Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.”^[ii]

The rationale for omitting contrast in favor of “shorter and cheaper” bpMRI is based on the PRIME study, a comparison study with 490 men who had both types of scan. The study found that bpMRI was noninferior to mpMRI (that is, roughly comparable) in detecting clinically significant prostate cancer (csPCa) and clinically insignificant prostate cancer (ciPCa). This table summarizes their data:

	Detection of csPCa	Detection of ciPCa
bpMRI	143 of 490 men (29.2%)	45 of 490 men (9.2%)
mpMRI	145 of 490 men (29.6%)	47 of 490 men (9.6%)

The authors point out that these results depend on high quality imaging; naturally, their own research centers were equipped with powerful magnets and experienced personnel. Still, their vision is reasonable when you look at the big picture. They write, “With approximately 4 million prostate MRIs performed globally annually, adopting biparametric MRI could substantially increase scanner throughput and reduce costs worldwide.” Point well taken.

Currently, bpMRI is most used when an IV contrast agent is not advisable due to a patient’s poor kidney function or allergic reaction to gadolinium-based contrast agents.

However, there are cases in which DCE will pick up cancer that bpMRI can miss:

1. PI-RADS 3 lesions that have ambiguous diffusion restriction on DWI. In these cases, DCE can raise confidence that the suspicious area is cancer.
2. In small Gleason 7 tumors, DCE can identify early abnormal blood flow before diffusion restriction becomes definitely apparent.
3. Some things can obscure DWI quality (patient movement; inadequate imaging b-values).
4. DCE can rule cancer out when non-cancerous conditions like post-biopsy artifacts, inflammation or infection mimic cancer on bpMRI.

There is little doubt that it’s desirable to make bpMRI more widely available, especially in areas where demand exceeds availability. Since bpMRI scans average 15-20 minutes compared to 35-40 minutes for mpMRI, it frees up magnet time so more patients can be scanned in a day. And there is little doubt that healthcare insurance will favor the less expensive scan. However, at the Sperling Prostate Center, we value avoiding shortcuts. We want the most thorough portrait of each patient’s prostate and any cancer it may contain. Of course, we perform expert, high quality bpMRI for those who need to omit the DCE sequence, yet mpMRI is appropriate for the majority of our patients. In short, everyone knows the saying that two heads are better than one. At the Sperling Prostate Center, when it comes to prostate MRI, three sequences are better than two.

NOTE: This content is solely for purposes of information and does not substitute for diagnostic or medical advice. Talk to your doctor if you are experiencing pelvic pain, or have any other health concerns or questions of a personal medical nature.

References

[i] Katelaris N, Bolton D, Weerakoon M et al. Current role of multiparametric magnetic resonance imaging in the management of prostate cancer. Korean J Urol 2015;56:337-45.
[ii] Ng ABCD, Asif A, Agarwal R, Panebianco V et al. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA. 2025 Oct 7;334(13):1170-1179.